Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________ FORM 10-K ________________________________________________________ (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Numb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from__________to__________ Commission File No. 001-38220 Angi Inc. (Exact name of Registrant as specified in its charter) Delaware 82-1204801 (State or other jur ...

Financial Performance - In 2025, CDW generated net sales of $22.4 billion, a 6.8% increase from $21.0 billion in 2024[47] - Net sales for the year ended December 31, 2025, totaled $22,424.1 million, representing a 6.8% increase from $20,998.7 million in 2024[202] - Gross profit for 2025 rose by $271 million, or 5.9%, with a gross profit margin of 21.7%, a decrease of 20 basis points from the previous year[176] - Total gross profit for the year ended December 31, 2025, was $4,873.4 million, a 5.9% increase from $4,602.4 million in 2024[180] - Operating income for 2025 was $1,655.6 million, reflecting a slight increase of 0.3% compared to 2024, with an operating income margin of 7.4%[174] - Operating income for the year ended December 31, 2025, increased by $4 million, or 0.3%, to $1,656 million compared to $1,651 million for 2024[177] - Non-GAAP net income for 2025 was $1,323.0 million, compared to $1,287.2 million in 2024, with non-GAAP net income per diluted share increasing to $10.02 from $9.52[170] - Non-GAAP operating income for 2025 was $1,996.7 million, or 8.9% of net sales, compared to $1,947.0 million, or 9.3% of net sales in 2024[199] - Free cash flow for 2025 was $1,088.1 million, down from $1,154.7 million in 2024, indicating a decrease of 5.7%[203] Sales Breakdown - The US business accounted for approximately 90% of net sales, with five dedicated customer channels each generating over $1.7 billion in net sales[29] - CDW's net sales from hardware amounted to $16.1 billion, representing 71.6% of total net sales in 2025[47] - Net sales from software reached $4.2 billion, accounting for 18.7% of total net sales in 2025[47] - Corporate segment net sales increased by $605 million, or 6.8%, driven by higher customer demand in software and hardware products[186] - Small Business segment net sales rose by $203 million, or 13.3%, primarily due to increased demand for notebooks/mobile devices and software[188] - Public segment net sales increased by $378 million, or 4.6%, attributed to higher demand in software and services across various customer channels[190] - Other segment net sales increased by $240 million, or 9.7%, driven by growth in notebooks/mobile devices and services within UK and Canada operations[192] Operational Insights - The company operates two distribution centers in North America and one in the UK, handling approximately 22 million units annually[35] - Drop-shipment arrangements represented about 51% of total North America net sales in 2025[36] - The company has approximately 14,800 coworkers globally, with 11,200 in the US and 3,600 internationally[51] - Over 50% of US net sales are generated by account managers with more than seven years of tenure[51] - The company maintains a diverse solutions portfolio with over 100,000 products and services from more than 1,000 brands, delivered through approximately 10,500 customer-facing employees[165] Strategic Initiatives - The company plans to realign its customer-facing organization into three reportable segments: Commercial, Government, and Education, effective January 1, 2026[30] - The company focuses on advanced digital transformation solutions, leveraging cloud-native deployment, DevOps, AI, and automation[49] - The company plans to further invest in AI capabilities to drive scale and efficiency across operations[73] Risk Factors - The company operates in a highly competitive industry, facing substantial competition from resellers, manufacturers, and service providers, which could harm financial performance[76] - Cybersecurity threats and data breaches could significantly impact business operations and reputation, with potential legal and regulatory consequences[89] - The reliance on cloud-based solutions may disrupt traditional business models and increase direct sales to customers, impacting hardware sales[78] - The ability to attract and retain key personnel is crucial for business success, with competitive labor markets increasing the risk of higher costs and turnover[92] - The company is exposed to accounts receivable risks, particularly during economic downturns, which could impact cash flows[100] - Inventory risks are heightened due to rapid technological changes and potential obsolescence, affecting business operations[101] - Legal and regulatory compliance risks could result in fines or contract terminations, adversely affecting business operations[118] Financial Position - As of December 31, 2025, the company had a total debt outstanding of $5.6 billion and $353 million in obligations under inventory financing agreements[128] - The company has $1.9 billion available to borrow under its senior unsecured revolving loan facility[128] - The company reported $635 million in variable rate debt outstanding, exposing it to interest rate risk[130] - Total unsecured indebtedness as of December 31, 2025, was $5.6 billion, with compliance to covenants under credit agreements[209] - The company entered into a new credit agreement in December 2025, increasing its borrowing capacity by $650 million[208] Shareholder Returns - The company declared a quarterly cash dividend of $0.630 per share, payable on March 10, 2026[149] - During the three months ended December 31, 2025, the company repurchased a total of 1.1 million shares of its common stock[151] - The average price paid per share for repurchases in October, November, and December 2025 was $155.34, $143.05, and $143.46 respectively[151] - The company has approximately $685 million remaining under its share repurchase program as of December 31, 2025[152]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 1-12882 BOYD GAMING CORPORATION (Exact name of registrant as specified in its charter) Nevada 88-0242733 (State or other jurisdiction of incorporation o ...

Acquisition and Strategic Growth - Abbott entered into a definitive agreement to acquire Exact Sciences Corporation, expected to enhance its presence in the cancer diagnostics market[18] - Abbott's acquisition of Exact Sciences Corporation is expected to cost approximately $21 billion, with a total enterprise value of $23 billion, including $1.8 billion of net debt[145] - The company may pursue acquisitions and strategic alliances, which could incur significant expenses and impact profitability if not successfully integrated[68] Workforce and Employee Programs - As of December 31, 2025, Abbott employed approximately 115,000 people, with 69% based outside the U.S.[42] - Abbott has an integrated global talent management process that supports employee development and succession planning[43] - Abbott's global wellness programs, including the "Exercise Across Abbott" initiative, saw participation from over 50,000 employees across 84 countries in 2025[48] - Abbott provides market competitive compensation and benefits, including financial support for employees with student loan debt and a global long-term incentive program[49] Product Segments and Sales Performance - Abbott's Established Pharmaceutical Products segment includes a broad line of branded generic pharmaceuticals, primarily marketed in emerging markets[20] - The Diagnostic Products segment includes core laboratory systems and rapid diagnostics for infectious diseases, contributing to Abbott's competitive edge in technology[25][26] - Abbott's Nutritional Products segment features a wide range of pediatric and adult nutritional products, including Similac and Ensure brands, targeting both consumers and healthcare professionals[27][30] - The Medical Devices segment includes advanced products for cardiovascular diseases and diabetes care, with a focus on continuous glucose monitoring systems[32][34] - Abbott's revenues in 2025 were significantly driven by the Medical Devices and Established Pharmaceuticals segments, with international sales comprising 61% of consolidated net sales[144] - Abbott's sales growth in emerging markets increased by 5.1% in 2025, representing 37% of total company sales, despite a decline in COVID-19 testing-related sales[147] - The Medical Devices segment saw a sales increase of 11.9% in 2025, with continuous glucose monitoring systems generating $7.6 billion in sales[148] - The Established Pharmaceutical Products segment saw an 8.0% increase in sales in key emerging markets, with a total of $4.167 billion in 2025[167] Financial Performance and Position - Abbott's consolidated indebtedness was approximately $12.9 billion as of December 31, 2025, and plans to fund the Exact Sciences acquisition with about $20 billion of borrowings[76] - Abbott's cash and cash equivalents totaled $8.9 billion as of December 31, 2025, compared to $8.0 billion in 2024, while long-term debt decreased to $12.9 billion[154] - Abbott's operating margin improved to 18.2% in 2025, up from 16.3% in 2024, reflecting margin improvement initiatives[147] - The company declared dividends of $2.40 per share in 2025, a 7.1% increase from $2.24 per share in 2024, with total dividends paid amounting to $4.1 billion[155] Regulatory and Compliance Challenges - The company is subject to comprehensive government regulations affecting product development, marketing, and distribution, which can significantly impact operational costs and timelines[50] - Abbott's products are subject to rigorous FDA regulations, and non-compliance could result in significant financial penalties and operational disruptions[79] - Legal and regulatory risks, including compliance with government benefit program regulations, could impose new obligations and restrict Abbott's operations, adversely affecting revenues[82] - The regulatory environment regarding data privacy and security is becoming more complex, with significant compliance obligations and potential penalties for noncompliance[60] Market Risks and Competitive Landscape - Abbott's competitive landscape includes pressures from generic drug substitutions and innovations from other healthcare companies[24][31] - The company faces intense competition, with competitors potentially introducing superior products or technologies that could negatively affect Abbott's market position[92] - Abbott anticipates continued pressure on healthcare product pricing due to governmental cost containment efforts and budgetary pressures on payors[56] - Approximately 61% of Abbott's net sales in 2025 came from international markets, exposing the company to geopolitical and macroeconomic risks[88] Research and Development - Abbott's research and development efforts require substantial ongoing expenditures without assurance of commercial success, which could lead to revenue and profitability declines[72] - Research and development (R&D) expenses increased to $2.9 billion in 2025, driven by higher spending on various projects[179] - Abbott plans to allocate approximately 7% of total sales to research and development spending in 2026, focusing on competitive project management[214] - The company is actively developing numerous pharmaceutical, medical device, diagnostic, and nutritional products, with a focus on geographic expansion and product enhancements[198][210] Legal Matters - Abbott is involved in 1,760 lawsuits related to its specialty infant formula products, with significant legal challenges impacting its financial position[118] - The U.S. Department of Justice is conducting a criminal investigation into Abbott's powdered infant formula manufacturing, which may lead to further legal and financial implications[119] - Abbott is engaged in ongoing discussions with the IRS regarding disputed items in the SNODs from 2017 to 2020[193] Economic and Currency Factors - Abbott's profitability is influenced by the U.S. dollar's exchange rate against other currencies, which affects the reported value of its assets, liabilities, and cash flows[93] - Economic deterioration in certain countries could increase the time to collect trade receivables, negatively impacting Abbott's cash utilization[96]

Financial Performance - Revenues for the year ended December 31, 2025 were essentially flat at $7,705.9 million, compared to $7,736.0 million for the prior year[241]. - Revenues for the year ended December 31, 2025 decreased by $30.1 million, or 0.4%, to $7,705.9 million from $7,736.0 million in the prior year[268]. - Revenues in the integrated and embedded solutions service line increased by $211.6 million, or 6.6%, while revenues in the point of sale and software solutions service line decreased by $190.9 million, or 12.6%[269]. - Consolidated operating income for the year ended December 31, 2025 was $1,754.6 million, down from $1,974.5 million, with an operating margin of 22.8% compared to 25.5% in the prior year[275]. - Income from continuing operations was $1,128.7 million, compared to $1,359.0 million for the prior year[283]. - Diluted earnings per share for continuing operations decreased to $4.43 from $5.04 in the prior year[284]. Cost Management - Merchant Solutions segment operating income and operating margin for the year ended December 31, 2025 increased due to cost reduction activities associated with the transformation program[241]. - Cost of service increased by $79.9 million, or 3.9%, to $2,113.4 million, with cost of service as a percentage of segment revenues rising to 27.4% from 26.3%[270]. - Selling, general and administrative expenses decreased by $262.9 million, or 8.4%, to $2,857.3 million, with expenses as a percentage of segment revenues at 37.1% compared to 40.3% in the prior year[272][273]. - Corporate expenses increased by $382.4 million, or 43.4%, to $1,263.3 million, primarily due to higher acquisition and transformation costs[274]. Transformation Initiatives - The company expects transformation initiatives to generate more than $650 million of annual run-rate operating income benefit by the first half of 2027[245]. - The company continues to assess its business portfolio for potential asset dispositions to streamline operations and create shareholder value[244]. Acquisitions and Divestitures - The company acquired 100% of Worldpay for approximately $6.2 billion in cash and 43.3 million shares of common stock, while divesting its Issuer Solutions business for approximately $7.7 billion in cash[236]. - The Issuer Solutions business has been classified as a discontinued operation, with historical operations presented accordingly[237]. Cash Flow and Financing Activities - Operating activities generated net cash of $2,656.6 million for the year ended December 31, 2025, a decrease from $3,057.6 million in 2024, primarily due to increased cash use in net working capital[296]. - The company used net cash in investing activities of $230.3 million in 2025, including $352.1 million for acquisitions and $617.8 million for capital expenditures[297]. - Financing activities provided net cash of $3,732.5 million in 2025, compared to a net cash usage of $2,291.8 million in 2024[298]. - Proceeds from long-term debt were $12,300.9 million in 2025, an increase from $9,635.0 million in 2024, while repayments were $7,207.6 million in 2025[299]. - The company repurchased 13.2 million shares of common stock for $1,191.0 million in 2025, with an average price of $84.61 per share[302]. - Dividends paid to common shareholders amounted to $238.5 million in 2025, down from $252.8 million in 2024[303]. Debt and Credit Facilities - The company has $16.4 billion in aggregate principal amount of senior unsecured notes outstanding as of December 31, 2025[304]. - The company entered into a $7.25 billion revolving credit facility, with $5.75 billion available immediately and an additional $1.5 billion upon closing the acquisition of Worldpay[322]. - As of December 31, 2025, there were $1.5 billion in borrowings outstanding under the revolving credit facility at an interest rate of 5.11%[325]. - The company established a $2.0 billion commercial paper program, backstopped by the revolving credit facility, with no net borrowings as of December 31, 2025[326][328]. - The company obtained $7.7 billion in committed bridge financing for the acquisition of Worldpay, reduced to $6.2 billion upon entering the revolving credit facility[332]. Impairment and Asset Valuation - The company recognized a goodwill impairment charge of $33.2 million in discontinued operations during Q2 2025 due to the Issuer Solutions disposal group being classified as held for sale[344]. - The company recognized a charge of $160.4 million to reduce the carrying amount of the Issuer Solutions disposal group to estimated fair value less costs to sell during the year ended December 31, 2025[348]. - The company regularly evaluates whether events indicate that the carrying amount of long-lived assets may not be recoverable, assessing potential impairment at the asset group level[347]. Foreign Currency and Interest Rate Risk - The company is exposed to foreign currency exchange rate fluctuations, but the effect on consolidated revenues and operating income for the year ended December 31, 2025, was insignificant[358]. - The company has designated €800 million Euro-denominated senior notes due March 2031 as a hedge of its net investment in Euro-denominated operations to offset volatility due to foreign currency exchange rate changes[361]. - The company has interest rate swaps with a total notional amount of $1.5 billion to hedge interest rate risk on a portion of its variable-rate debt[364]. - A hypothetical increase of 50 basis points in applicable interest rates would increase annual interest expense by approximately $1.7 million and annual interest income by approximately $34.4 million[366]. - The exposure of net income to interest rate changes is partially mitigated as increases in rates would raise both interest income and interest expense[365].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34674 Calix, Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | | 68-0438710 | | --- | --- | --- | | (State or O ...

Financial Performance - In 2025, the company achieved total revenue of $1.9 billion, primarily from sales of its COVID vaccines[22]. - The company expects to drive revenue growth in 2026 from long-term partnerships in the UK, Canada, and Australia, along with strong uptake of mNEXSPIKE in the U.S.[37]. Product Development and Clinical Trials - The company is advancing a pipeline of development candidates across oncology, rare disease, and infectious disease, with eight Phase 2 and Phase 3 clinical trials underway for intismeran[23]. - The company has a diverse development pipeline consisting of 35 therapeutic and vaccine programs, with 6 in late-stage development[58]. - The company continues to advance its early-stage pipeline, including oncology programs and multiple early-stage vaccine programs[38]. - The company anticipates pivotal trial data readouts in 2026 across its oncology, rare disease, and infectious disease portfolios, with plans to launch several new infectious disease products[37]. - The Phase 3 trial for mRNA-1018 is expected to begin in early 2026, following CEPI's investment[78]. - The Phase 3 trial of the trivalent vaccine candidate mRNA-1403 has enrolled about 38,000 participants, focusing on older adults who are at the highest risk of severe outcomes[95]. - The ongoing Phase 1/2 study of mRNA-4349 includes cohorts for first-line metastatic melanoma and first-line metastatic NSCLC[122]. - The registrational study for mRNA-3927 has reached target enrollment, and an infant dose-finding study is also ongoing[131]. Regulatory Approvals - The company has regulatory filings under review for its seasonal flu+COVID combination vaccine candidate (mRNA-1083) and expects a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026, for mRNA-1010[24]. - The FDA has approved the 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years and all adults 65 years and older, with approvals received in 40 countries[64]. - The RSV vaccine (mRNA-1345 or mRESVIA) has been approved for adults 60 years and older, with recommendations for unvaccinated individuals aged 75 and older and high-risk individuals aged 50-74[66]. - The FDA accepted the BLA for mRNA-1010 for review, with a PDUFA goal date of August 5, 2026[71]. Manufacturing and Production - The company streamlined its production sites into a global manufacturing network, adding three facilities in the UK, Canada, and Australia to enhance local access to mRNA vaccines[26]. - The Marlborough biomanufacturing facility, completed in 2025, is designed for speed and scalability, and began shipping patient batches in September 2025[141]. - mRNA manufacturing facilities in the UK, Canada, and Australia were fully licensed in 2025, with multi-year commitments from local governments to purchase mRNA products[142]. - The company has invested significantly in manufacturing process science to produce mRNA medicines at scales ranging from micrograms to kilograms[52]. Strategic Collaborations - The company entered into a strategic collaboration with Recordati to advance its propionic acidemia therapeutic (mRNA-3927) through final stages of clinical development[25]. - Moderna's strategic alliance with Merck for personalized mRNA cancer vaccines includes an upfront payment of $200 million and a subsequent option exercise fee of $250 million[178][179]. - The collaboration with BARDA for the development of mRNA-1273, the original COVID vaccine, had a maximum award of approximately $1.8 billion, concluding on June 15, 2025[183]. - The company has entered into a collaboration with Recordati to advance investigational PA therapeutic (mRNA-3927) through clinical development and commercialization[182]. Intellectual Property - Moderna's intellectual property estate includes over 260 issued or allowed U.S. patents and more than 140 granted patents outside the U.S., with most patents not expiring until at least 2033[189]. - The projected expiration for U.S. patents covering the company's approved products, such as Spikevax and mNEXSPIKE, is 2041, while European patents are set to expire in 2036[198]. - The company maintains a multi-program effort to develop vaccines for potential future pandemics, targeting diseases such as Zika, dengue, HIV, and Nipah virus[206]. - The company's trademark portfolio includes at least 1,400 registrations and 180 pending applications across more than 55 jurisdictions[214]. Research and Innovation - The company has implemented AI-driven data analytics to optimize drug design, clinical trial operations, and manufacturing processes, enhancing efficiency and product quality[164][165][166]. - In early 2023, Moderna began a collaboration with OpenAI to integrate AI capabilities across various business functions, including legal, research, and manufacturing[167]. - The company is focused on expanding its modalities, which allows for rapid acceleration of programs based on learnings from earlier initiatives[56]. Economic Impact - Norovirus causes an estimated 685 million illnesses and 200,000 deaths annually, with a significant economic impact of approximately $60 billion per year globally[90]. - The economic burden of norovirus in the U.S. is estimated at $2 billion annually, with 20 million infections and 100,000 hospitalizations each year[90].

Exhibit 99.1 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates 2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, NJ, Feb. 20, 2026 – Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with r ...